Caladrius Biosciences ROA 2024

Caladrius Biosciences Aktienanalyse

What does Caladrius Biosciences do?

Caladrius Biosciences Inc was founded in 1980 as a pharmaceutical biotechnology company and is headquartered in Basking Ridge, New Jersey. The company focuses on developing cellular therapies for the treatment of serious diseases. Caladrius Biosciences aims to improve the lives of patients with unmet medical needs by developing novel and innovative therapies based on neuroscientific, immunological, and regenerative approaches. The business model of Caladrius Biosciences is based on researching and developing products that focus on the needs of patients. The goal is to concentrate on innovative and groundbreaking therapies that can treat diseases that have not been adequately treated before. The company has developed a portfolio of groundbreaking products based on stem cell, immune, and regenerative therapies. Caladrius Biosciences has three different business areas: - The first business area is its subsidiary PCT, LLC, which offers clinical manufacturing services in the field of clinical cell therapies. The subsidiary provides a scalable platform for the production of individual cell-based therapies. - The second business area is conducting clinical trials, including in the field of cardiovascular diseases. Caladrius Biosciences collaborates closely with clinics, doctors, and other professionals to demonstrate the potential of its own products through clinical studies. - The third area is the development of innovative therapies for diseases that previously could not be treated. The company is working on regenerative, immunological, and stem cell therapies. Caladrius has various products in development based on novel technologies, such as stem cell therapy. The company focuses on cardiovascular diseases, autoimmune diseases, and cancer. One of the flagship products of the company is CLBS201, which is a stem cell treatment for coronary heart disease. It is an autologous cell-based product derived from a patient's bone marrow and is used in combination with angioplasty, a minimally invasive surgical procedure to widen narrowed or blocked blood vessels. In summary, Caladrius Biosciences Inc is a leading biopharmaceutical company that focuses on developing innovative stem cell and immune therapies for the treatment of serious diseases. The company prioritizes the needs of patients and has established a unique position in the regenerative and cell-based therapy industry. Caladrius Biosciences pursues a long-term and sustainable growth model by relying on innovative technologies and clinical trials to continue developing groundbreaking products. In short, Caladrius Biosciences tirelessly works to improve the lives of people and cure diseases that were previously considered incurable. Caladrius Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Caladrius Biosciences's Return on Assets (ROA)

Caladrius Biosciences's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Caladrius Biosciences's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Caladrius Biosciences's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Caladrius Biosciences’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Caladrius Biosciences Stock

What is the Return on Assets (ROA) of Caladrius Biosciences this year?

The Return on Assets (ROA) of Caladrius Biosciences is -0.74 undefined this year.

What was the ROA of Caladrius Biosciences compared to the previous year?

The ROA of Caladrius Biosciences has increased by 162.23% compared to the previous year.

What consequences do high ROA have for investors of Caladrius Biosciences?

A high ROA is advantageous for investors of Caladrius Biosciences, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Caladrius Biosciences?

A low ROA can be unfavorable for investors of Caladrius Biosciences as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Caladrius Biosciences affect the company?

An increase in ROA of Caladrius Biosciences can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Caladrius Biosciences impact the company?

A reduction in the ROA of Caladrius Biosciences can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Caladrius Biosciences?

Some factors that can influence the ROA of Caladrius Biosciences include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Caladrius Biosciences important for investors?

The ROA of Caladrius Biosciences is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Caladrius Biosciences take to improve ROA?

To improve ROA, Caladrius Biosciences can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Caladrius Biosciences pay?

Over the past 12 months, Caladrius Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Caladrius Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Caladrius Biosciences?

The current dividend yield of Caladrius Biosciences is .

When does Caladrius Biosciences pay dividends?

Caladrius Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Caladrius Biosciences?

Caladrius Biosciences paid dividends every year for the past 0 years.

What is the dividend of Caladrius Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Caladrius Biosciences located?

Caladrius Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Caladrius Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Caladrius Biosciences from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Caladrius Biosciences pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Caladrius Biosciences in the year 2023?

In the year 2023, Caladrius Biosciences distributed 0 USD as dividends.

In which currency does Caladrius Biosciences pay out the dividend?

The dividends of Caladrius Biosciences are distributed in USD.